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Felix Jost, Enrico Schalk, Daniela Weber, Hartmut Do¨hner, Thomas Fischer & Sebastian Sager
Abstract—Objective: Neutropenia is an adverse event com-
monly arising during intensive chemotherapy of acute myeloid
leukemia (AML). It is often associated with infectious compli-
cations. Mathematical modeling, simulation, and optimization of
the treatment process would be a valuable tool to support clinical
decision making, potentially resulting in less severe side effects
and deeper remissions. However, until now, there has been no
validated mathematical model available to simulate the effect
of chemotherapy treatment on white blood cell (WBC) counts
and leukemic cells simultaneously. Methods: We developed a
population pharmacokinetic/pharmacodynamic (PK/PD) model
combining a myelosuppression model considering endogenous
granulocyte-colony stimulating factor (G-CSF), a PK model
for cytarabine (Ara-C), a subcutaneous absorption model for
exogenous G-CSF, and a two-compartment model for leukemic
blasts. This model was fitted to data of 44 AML patients
during consolidation therapy with a novel Ara-C plus G-CSF
schedule from a phase II controlled clinical trial. Additionally,
we were able to optimize treatment schedules with respect to
disease progression, WBC nadirs, and the amount of Ara-C and
G-CSF. Results: The developed PK/PD model provided good
prediction accuracies and an interpretation of the interaction
between WBCs, G-CSF, and blasts. For 14 patients (those with
available bone marrow blast counts), we achieved a median 4.2-
fold higher WBC count at nadir, which is the most critical time
during consolidation therapy. The simulation results showed that
relative bone marrow blast counts remained below the clinically
important threshold of 5%, with a median of 60% reducion
in Ara-C. Conclusion: These in silico findings demonstrate the
benefits of optimized treatment schedules for AML patients.
Significance: Until 2017, no new drug had been approved for
the treatment of AML, fostering the optimal use of currently
available drugs.
Index Terms—Myelosuppression, Population PK/PD modeling,
cytarabine, lenograstim, treatment schedule optimization.
I. INTRODUCTION
CHEMOTHERAPY treatment of acute myeloid leukemia(AML) is usually divided into an induction phase and a
consolidation phase.
The goal of the induction phase is the eradication of blasts.
By blasts, we refer to a combination of aberrant/leukemic
and physiological blasts that are cytologically ≥ 20% in the
bone marrow (BM) at the time of AML diagnosis [1]. The
standard treatment consists of intensive chemotherapy with
three days of anthracycline (idarubicin or daunorubicin) and
seven days of cytarabine (Ara-C). To monitor the relative
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numbers of blasts in each cycle, BM aspirations are collected
and analyzed. After the induction phase, the relative number of
blasts should be below 5% in the BM (assessed by cytology)
and not measurable in the circulating blood.
In this study, we are interested in the subsequent consol-
idation phase. While the goal to reduce the blasts as much
as possible to prevent a relapse is identical between the
two phases, the conflicting objective to avoid complicating
infections plays an important role in the consolidation phase.
Neutropenia is characterized by decreased counts of neutrophil
granulocytes in the peripheral blood. It is a serious and com-
mon adverse event arising during the treatment with cytotoxic
chemotherapy of AML. This form of white blood cell (WBC)
suppression in the BM (myelosuppression) is responsible for
a higher risk of infections and consequently for delayed, dose-
reducing or stopped treatments, longer hospitalization periods,
and mortality as the worst case.
The phase consists of up to four consolidation cycles (CCs)
of intermediate- or high-dose Ara-C or allogeneic hematopoi-
etic stem cell transplantation [1]. In this work, we focus
on grade 4 leukopenia (WBC count < 1 G/L) [2] in the
consolidation phase. In clinical practice, grade 4 leukopenia is
equivalent to grade 4 neutropenia (absolute neutrophil count <
0.5 G/L) [2] and was chosen because the available measured
WBC counts were not further specified into granulocytes
(neutrophils, eosinophils, and basophils), monocytes, or lym-
phocytes (T cells and B cells). In each cycle of cytotoxic
chemotherapy, the WBCs decrease from their normal range
to a critical value close to 0 G/L. The interval in which the
WBCs are below a certain grade is defined as leukopenia, and
the time from the start of treatment until WBC recovery above
this threshold is called WBC recovery time.
One standard AML consolidation treatment consists of Ara-
C 3 g/m2 intravenous (body surface area [BSA]-adjusted)
lasting 3 hours every 12 hours on days 1, 3 and 5 (D135) for
patients aged 60 years and younger, which was investigated by
Mayer et al. in 1994 [3]. Older patients (> 60 years) receive
an intermediate dosage of 1 g/m2 Ara-C infusions in the same
intervals (d135). In recent years, studies have proposed a dense
treatment schedule at which high-dose Ara-C is administered
on days 1, 2 and 3 (D123) to reduce the WBC recovery time
and increase survival [4], [5].
In addition to new treatment schedules, the administration of
granulocyte-colony stimulating factor (G-CSF) can reduce the
depth and duration of leukopenia [6]. Hematopoietic growth
factors such as G-CSF regulate blood cell production, includ-
ing survival, proliferation, and differentiation of hematopoi-
etic stem cells and stimulation of mature cell functions by
activating signal transduction pathways [7]. The impact of
G-CSF was enhanced by the clinical development of a re-
combinant human G-CSF, called filgrastim, in 1986 for the
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prevention of leukopenia and hematopoietic stem cell mobi-
lization before autologous or allogeneic hematopoietic stem
cell transplantation [8]. The European Society for Medical
Oncology suggests daily filgrastim administration after the last
day of chemotherapy until a sufficient/stable postnadir absolute
neutrophil count recovery, respectively, for approximately 10
days [9]. On top of chemotherapy, the additional burden of
daily filgrastim administration was reduced by the invention of
pegfilgrastim, a pegylated form of filgrastim. The inclusion of
filgrastim into a polyethyleneglycol polymer prolongs the half-
life from 3.5 hours to 46-62 hours such that the permanence
of pegfilgrastim in blood circulation is up to 16 days after
a single administration [10], replacing the frequent filgrastim
administrations. In addition to filgrastim, lenograstim was
developed, which is a physicochemically, immunologically
and biologically identical glycosylated recombinant G-CSF to
human G-CSF [10].
In this work, we used nonlinear mixed-effects pharma-
cokinetic (PK)/pharmacodynamic (PD) modeling approaches
together with clinical data to explore the impact of different
treatment schedules and the administration of lenograstim on
WBCs and leukemic blasts. In recent years, PK/PD models
for endogenous G-CSF and blood cells such as neutrophils
or leukocytes [11] and several PK models for exogenous
G-CSF (filgrastim [12], [13], [14], [15], pegfilgrastim [16],
[13], [17] and lenograstim [18], [19], [20], [21], [22]) have
been presented. However, few PK/PD models combining en-
dogenous and exogenous G-CSF and leukocytes [23], [24]
or neutrophils [25], [26], [27] for the prediction of myelo-
suppression have been published, particularly not for Ara-
C-derived myelosuppression during consolidation therapy of
AML patients. Therefore, we developed a population PK/PD
model modifying, and extending previously published models
to analyze the inverse correlation between G-CSF and leuko-
cytes during different Ara-C and lenograstim schedules. The
consideration of leukemic blasts and their interaction with
leukocytes, comparable to previous works [28], [29], [30],
completed the model. We used it in an optimization setting.
Here, in comparison to previous works [31], [32], [33], we
formulated a multiobjective optimization problem considering
terms for disease progression, state of health, and therapy
costs.
In summary, we developed models and algorithms for a
computational framework to individually simulate, analyze,
and optimize the consolidation treatment schedules of Ara-C
and lenograstim.
II. PATIENTS AND METHODS
A. Patients and clinical data
Data from the AMLSG 12-09 randomized controlled clin-
ical phase II trial [5] were provided by the Department of
Internal Medicine III, University Hospital Ulm, Ulm, Ger-
many and used for model development, fitting, validation,
and calibration. The dataset (denoted by Ulm in Figure 3(a))
included WBC count measurements (6-16 per cycle) from 86
Ara-C CCs, partitioned into one, two, and three consecutive
CCs from 20, 6, and 18 AML patients (median 65 years, 19
[43%] male), respectively, from 2010 and 2012, which were
treated with D123 (31 out of 86 CCs) or d123 (55 out of 86
CCs) schedules of Ara-C. Additionally, in most cycles before
Ara-C treatment (76 measurements), the relative number of
blasts in the BM and the category of BM cellularity (punctio
sicca, hypo-, normo- or hypercellular) were determined by
cytology via BM aspiration. 13 BM measurements were below
the limit of quantification and consequently exluded from
the analysis. The treatment schedule included 263 µg of
lenograstim administrations starting nine days after the start of
Ara-C treatment until hematological recovery, i.e., neutrophil
count > 0.5 G/L, was achieved. Nine of the patients (1 only
in the first cycle and 7 CCs each for d123 and D123) did not
receive lenograstim.
For the analysis in the subsequent section called Modeling
exogenous G-CSF, the patientwise cycles of the current dataset
were treated independently (although several cycles belong to
the same patient) and combined with the publicly available
dataset (denoted by MD in Figure 3(a)) from the supporting
information of [34]. This dataset was retrospectively collected
from records of clinical routine and provided by the Depart-
ment of Hematology and Oncology, Magdeburg University
Hospital, Magdeburg, Germany. The dataset consists of one,
two, and three consecutive CCs from nine, nine, and five pa-
tients, respectively, who received different treatment schedules
of D135, d135, D123 and D12.
In the section titled Modeling leukemic blasts the current
dataset was used for model fitting. In the following section
Model predictions and optimal treatment schedules, a subset
of 24 patients, for whom at least two CCs were available, were
used to perform model predictions. For the computation of
optimized treatment schedules, this subset was further reduced
to 14 patients for whom relative blast counts were available
in the last CC. The different subsets used in each section are
visualized as a diagram in Figure 1.
PK/PD model
The aim was to develop a population PK/PD model describ-
ing WBC counts and blasts of AML patients treated with Ara-
C and lenograstim during consolidation therapy. The model
development was guided by previously published models and
available WBC counts and blast measurements. The PK/PD
model by Quartino et al. [11] describing the proliferation
and differentiation of stem cells to mature neutrophils, and
its regulation by endogenous G-CSF was used as a starting
point. The developed PK/PD model is shown in Figure 2.
The two-compartment PK model (x1, x2) for Ara-C was
taken from [34] in which a detailed description and discussion
of the PK model was found. The hematopoiesis of WBCs
is modeled by a chain of three compartments representing
the proliferating stem cells xprol and differentiating cells xtr
in the BM released to the blood stream after maturation to
WBCs. Matured cells xwbc die by apoptosis with a death rate
constant kwbc. Ara-C is incorporated into the DNA leading
to cell death, such that a log-linear PD term as a first order
kinetics negatively influences the proliferation of stem cells,
equivalent to [34]. Two modifications of the myelosuppres-
sion model were implemented for our purposes. Instead of
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Clinical phase II trial
(AMLSG-12-9), [5]
44 Patients∗
Leno yes no
D123 13 5
d123 23 4
Modeling
leukemic blasts
44 Patients∗
Leno yes no
D123 13 5
d123 23 4
Model predictions
24 Patients∗
Leno yes no
D123 6 2
d123 14 2
Optimal
treatment schedules
14 Patients
Leno yes no
D123 6 0
d123 7 1
Clinical data from [34]
23 Patients
Leno no
D135 12
d135 9
D123 1
D12 1
Modeling
exogenous G-CSF
128 CCs
Leno yes no
D135 0 24
d135 0 14
D123 24 9
d123 48 7
D12 0 2
all
more than 1 CC
with blast measurement in last CC
allall
Fig. 1: Diagram of the two datasets and their subsets used in
the different sections and for the pharmacodynamic (PD) mod-
eling. Choices of subsets were based upon data availability,
e.g., administration of lenograstim (Leno), granulocyte-colony
stimulating factor (G-CSF), and numbers of consolidation
cycles (CCs). One patient ∗ received 1 CC without and 2 CCs
with Leno, the data were split.
three, we used one transit compartment xtr, still guaranteeing
a reliable interpretation of the mean maturation time and
no loss of model accuracy. A detailed discussion is given
in [34]. Furthermore, the subcutaneous (s.c.) administration
of lenograstim was modeled by a chain of three compart-
ments describing the effect of enhanced proliferation and
maturation. The first compartment is a depot compartment
with the constant F representing the bioavailability of s.c.
adiminstration of lenograstim which was determined to be
30% [35]. As lenograstim has an equivalent chemical structure
than endogenous G-CSF and they bind to the same receptors
[10], lenograstim is released to compartment xg via the first-
order absorption rate constant ka possitively affecting the
production of WBCs. As no endogenous G-CSF measurements
were available, several parameters were fixed to values from
publications (see Table I). Motivated by the desire to quantify
the effect of treatments on the disease, we included the
leukemic blasts as a separate cell line. The sequential hierarchy
[36], [37] of leukemic blasts (similar to WBC) is described
by the two compartments xl1 and xl2 which represent the
leukemic blasts in the bone marrow, respectively circulating
blood and was published in [38]. The leukemic blasts in the
bone marrow grow and proliferate with the first order rate p1.
During cell division a leukemic blast divides into two daughter
cells, so that the outflux from mitosis is 2p1xl1 . The outflux
is then seperated into the process of self-renewal by the rate
2p1a1kl with the fraction constant a1 determining the fraction
of daughter cells staying at the current differentiation stage
and cell movement by the rate 2p1(1− a1) to the consecutive
compartment. Leukemic cells are dying by the first order
rate d2. In contrast to the myelosuppression model, which
does not distinguish between self-renewal and differentiation
into the next compartment, the model of the leukemic blasts
takes this separation into account. As we concentrated on the
cytokine-dependent version of leukemic blasts, we used the
term klc from [30], [38] in which the interaction between
leukemic blasts and WBC counts is modeled through the
competition of endogenous G-CSF between the circulating
cells of both lineages. The term was derived from a quasi-
steady-state assumption of the G-CSF dynamics (see [30] for
a detailed discussion). The WBC-regulated elimination of G-
CSF kout was extended with circulating leukemic blasts xl2
because both linages make use of G-CSF. A numerical steady
state analysis was performed to determine the system behavior
until one and a half years after the start of the first CC. For
each patient, the validated model drives into a purely leukemic
steady state (xprol = xtr = xwbc = 0 and xl1, xl2 > 0) after
five months on average. Values for a1 and d2 were taken from
[38] and p1 was chosen as a half of the WBC proliferation
similar to [38] characterizing slow growing leukemic cells [39]
resulting in a duration of remission in the range of 4.1 to 8.1
months reported by [40]. To formulate the mathematical model
as a system of ordinary differential equations in a compact
form, we use the following definitions, i.e., for the PD effect
E on ktr, the zero-order production rate kin and first-order
elimination rate kout of G-CSF, and the G-CSF quasi-steady-
state term klc for the leukemic blasts, we define
E = slope ln(
x1
Vc MMAraC
+ 1)
kin = (ke,g + kANC B) Bg + ka xexo2
kout = (ke,g + kANC (xwbc + xl2))
klc =
1
1 + c1 xwbc + c2 xl2
.
All constants, control functions defining the administration of
Ara-C and lenograstim, parameters, and initial conditions are
specified in Table I. The time derivatives of all states are given
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Proliferating cells
xprol
Transit cells
xtr
Mature WBC
xwbc
endogenous GCSF
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ke,g + kANC B
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B
g
) γ
kprol = ktr
Ara-C (peripheral)
x2
Ara-C (central)
x1
E
k12
k21
k10Ara-C (uc)
slope
Leukemic blasts (bone marrow)
xl1
Leukemic blasts (blood)
xl2
klc =
1
1+c1 xwbc+c2 xl2
p1
2(1− a1klc)p1
d2
2p1
a1k
lc
Transit Comp.
xexo2
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xexo1
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Depot xD
Lenograstim (ul)
F kaka
ka
Fig. 2: Visualization of the final pharmacokinetic/pharmacodynamic model. The hematopoiesis of white blood cells (WBCs) is
described by two compartments representing the proliferation and differentiation within the bone marrow. The third compartment
describes the circulating matured WBCs. The sequential hierarchy (similar to WBC) of leukemic blasts is described by a two-
compartment model. Both linages interact by the competition of endogenous G-CSF. Ara-C affects proliferation of leukemic
blasts and WBCs. Lenograstim adminstration was modeled by a single pathway absorption model with two transit compartments
[22].
by
x˙1 = −(k10 + k12) x1 + k21 x2 + uc BSAdurc (1a)
x˙2 = k12 x1 − k21 x2 (1b)
x˙prol = −
(
xg
Bg
)β
ktr xprol +
(
xg
Bg
)γ
ktr(1− E) xprol (1c)
x˙tr =
(
xg
Bg
)β
ktr xprol −
(
xg
Bg
)β
ktr xtr (1d)
x˙wbc =
(
xg
Bg
)β
ktr xtr − kwbc xwbc (1e)
x˙g = kin − kout xg (1f)
x˙D = −ka F xD + ul 1000
Vg durl
(1g)
x˙exo1 = ka F xD − ka xexo1 (1h)
x˙exo2 = ka xexo1 − ka xexo2 (1i)
x˙l1 = (2a1klc − 1)p1 xl1 − p1E xl1 (1j)
x˙l2 = 2(1− a1klc)p1 xl1 − d2 xl2. (1k)
B. Measurement functions
The observed cell type measurements were WBC counts in
the circulating blood and relative blast counts in the BM. The
WBC count measurements were directly matched to the state
xwbc resulting in the corresponding measurement function
hwbc(t) = xwbc(t). (2)
The measurement function of the relative blast count was used
from previous publications [41], [33]:
hblasts(t) = 100
xl1(t) + 0.005 xtr(t)
CRij DB
(3)
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TABLE I: Model constants, patient-specific constants, model parameters, and initial values with their units and descriptions.
Constant Unit Value Description
PK model of Ara-C
k10 1/day 98.2920 Elimination rate of Ara-C
k12 1/day 2.6616 Distribution rate of Ara-C
k21 1/day 12.8784 Distribution rate of Ara-C
Volume Vc L 37.33 Volume of central compartment
MMAraC g/mol 243.217 Molecular mass of Ara-C
durc day 1/8 Infusion time
PD model of WBCs and leukemic blasts
kwbc 1/day 2.3765 Death rate of circulating WBCs
β - 0.234 Feedback of G-CSF on transit time
slopeG - 0.470 PD effect of Ara-C on γ
Bg ng/L 24.4 Endogenous G-CSF steady state
ke,g 1/day 0.592×24 Non-specific elimination rate constant
kANC 1/day 5.64×24 Neutrophil-dependent elimination rate
a1 - 0.875 Probability of self-renawal
p1 1/day 0.1 Leukemic cell proliferation rate
d2 1/day 2.3 Leukemic cell death rate
c1 L/109 0.01 G-CSF quasi steady-state feedback scaling factor
c2 L/109 0.01 G-CSF quasi steady-state feedback scaling factor
kANC 1/day 5.64×24 ANC dependent elimination rate
of endogenous G-CSF
PK model of lenograstim
F - 0.3 Bioavailability of s.c. administration from [35]
Vg L 14.5 Volume of distribution from [18]
durl day 0.0007 Infusion time
ke,exo 1/day 0.220×24 Elimination rate of exogenous G-CSF
BSA m2 [1.61, 2.07] Body surface area
uc(t) g/m2 [1, 3] Ara-C dosage
ul(t) µg [263, 324] Lenograstim dosage
Parameter Unit Description
ka 1/day Absorption rate of lenograstim
ktr 1/day Transition rate
γ – Feedback speed of G-CSF on WBCs
slope L/µmol PD effect of Ara-C on WBCs
B 109/L Baseline of WBC count
x0blasts 10
9/L Relative number of blasts
at start of consolidation therapy
State initial value Value State Value
x1, x2, xexo1, xexo2, xD 0 xg Bg
xprol, xtr (B kwbc)/ktr xl1 x0blasts(DB CR) − 0.005(B kwbc)/ktr
xwbc B xl2 B/99
with the cellularity factor of patient i in the j-th consolidation
cycle
CRij =

0.2 if hypocellular
0.4 if normocellular, years > 65
0.5 if normocellular, years ≤ 65
0.95 if hypercellular
(4)
and DB = 1012 being the approximated maximal tumor cell
burden in acute leukemias [42]. The assumed BM volume of
approximately 1 liter, being in the range of published values
[43], [44], allows to specify both lineages in [109 cells/L].
As the measurement method for determining the relative blast
counts in the BM did not differentiate between physiological
and leukemic blasts the original function was extended with
0.5% cells of the transit compartment. Nombella and Manz
[44] examined the range of the relative number of common
myeloid progenitors in the BM to be 0.2-0.8% represented in
the function by 0.5% cells of the transit compartment.
C. Model development and fitting
In a first step, the Ara-C version of Quartino’s myelosup-
pression model was extended through absorption models with
varying transit compartments decribing the s.c. administration
of lenograstim [22]. The models were fitted to a variety
of different consolidation cycles to determine the absorption
model which described the hematopoietic effects of lenogras-
tim administration best.
In a second step, a cytokine-dependent two-compartment
model describing the dynamics of leukemic blasts was in-
corporated and the complete PK/PD model was fitted to the
dataset of the Ara-C consolidation arm of the AMLSG 12-09
trial. For the analysis of the influence of the leukemic blast
lineage on the WBC lineage, we performed two parameter
estimations with and without consideration of leukemic blasts.
D. Model predictions and treatment schedule optimization
We analyzed the reliability of the newly developed model
with out-of-sample cross validations. We thus predicted the
last CC for all patients for whom measurements from more
than one CC were available, based on models fitted to the
measurements from all previous CCs. Additionally, we used
the individual models of 14 patients for whom relative blast
counts were available in the last CC for a mathematical
optimization of the treatment schedules of the last CC. We
compared clinically important indicators such as nadir values
and relative blast counts in the BM to the measured values.
Optimizing the treatment schedule for patient i ∈ {1, . . . , 20}
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was formulated as a minimization problem
min
xi(t),uic(t),u
i
l(t)
OBJi (5a)
s.t. x˙i(t) = f(x(t), θi, uic(t), u
i
l) (5b)
x(ti0) = x
i
0, (5c)
uic(t) ∈ [0, 2000] (5d)
uil(t) ∈ [0, 236] (5e)
on the individual time horizon ti0 to t
i
f with f(·) the
mathematical model (1) from the previous section, θi =
(Bi, kitr, slope
i, γi, pi1) the empirical Bayes estimate resulting
from the model fit to the measurements from all but the last
CC, xi0 the initial values of the ODE system at time point t
i
0,
uic(t) and u
i
l(t) the control functions of Ara-C and lenograstim
determining the administration schedule after optimization and
OBJi =α1 xil1(t
i
f ) + α2
∫ tif
ti0
1
xiwbc
2
(t)
dt
+ α3
∫ tif
ti0
uic(t)dt+ α4
∫ tif
ti0
uil(t)dt
the objective function consisting of four terms. The first term
denotes the number of leukemic cells in the bone marrow at
time tif representing the disease status at the end of the consol-
idation treatment. The second term reflects the health condition
of the patient during treatment (heavily penalizing small WBC
counts). The last two terms model the costs via the amount
of totally administered Ara-C and lenograstim, respectively.
Scalar weights α1, . . . , α4 allow the weighting of these terms
according to personalized, clinical, and ethical preferences.
Values of the weights were chosen by initial guesses and α1
was iteratively adapted until desired optimization outcomes
were met. The final values for the αi are presented in Table IV.
All optimization results were calculated for a time period
starting 10 days before the start of the actual Ara-C treatment
of the last CC (ti0) and ending with the time point of the
patient’s conducted BM puncture (tif ). This time horizon was
chosen to compare the optimized values with the measured
relative blast counts in the BM. The initial conditions x(ti0)
were derived from the individual models. We defined a hourly
time grid for model evaluation and for Ara-C infusions in
which Ara-C infusions can be optimized within the first 20
days. The control grid for Ara-C was restricted to the first
20 days so that no Ara-C infusions were placed at the end of
the time horizon. Lenograstim administrations were defined as
0.0007 day injections on the hourly grid once a day at 8 a.m.
The upper limit of hourly Ara-C infusions was chosen to be
2 g per hour, being the recommended maximum amount of a
high-dose treatment schedule for a patient under 60 years with
a BSA of 2 m2 which should not be exceeded [1]. The upper
limit of lenograstim administrations was chosen to be 263 µg
equivalently to the actual daily administered dose amount. The
infinite dimensional optimal control problem (5) was solved
by a direct collocation approach (simultaneous approach) in
which the control functions and the differential states are
simultaneously discretized by low order polynominals [45].
The resulting finite optimization problem is large scale due
to the introduction of additional optimization variables and
constraints, but highly structured such that tailored iterative
procedures can be applied to numerically calculate local
optimal solutions.
E. Model evaluation and software
We aligned the nonlinear mixed-effects modeling to estab-
lished PK/PD modeling approaches [46], [47], [11], [48]. In-
terindividual variability (IIV) was assumed to be log-normally
distributed, and residual variability was estimated using an
exponential error model. Model development was guided by
objective function values, uncertainty of parameters, agree-
ment of predicted and observed clinical end points and visual
evaluation of the results through visual predictive checks
with auto bin option, goodness-of-fit plots, and (individual)
weighted residuals over time.
Parameter estimation for the nonlinear mixed-effects mod-
eling approach was performed using the first-order conditional
estimation method with interaction algorithm implemented in
NONMEM 7.4 (ICON Plc., Dublin, Irland). Standard errors
were computed with the $COVARIANCE step in NONMEM.
Pirana (Certara, Princeton, USA) was used for NONMEM
execution and data analysis. The optimal control problems
were formulated in CasADi (Optimization in Engineering
Center (OPTEC), K.U. Leuven) [49] interfaced via Python
2.7 (Python Software Foundation) by applying a simultaneous
approach [50]. The system of ordinary differential equations
was discretized using direct collocation [50] with Lagrange
polynomials with Legendre collocation points of order 3, and
the nonlinear optimization problems were solved with Ipopt
3.12.3 [51].
III. RESULTS
A. Modeling exogenous G-CSF
The effect of lenograstim on WBC counts was visually
assessed by the cyclewise WBC dynamics after consolida-
tion therapy. Figure 3(a) shows that patients who received
lenograstim had a rapid increase of WBC counts during WBC
recovery. The evaluation of model fitting via the medians of
the individual mean absolute errors and root mean squared
errors in Table II revealed that the extended myelosupression
model with a s.c. absorption model and two transit com-
partments described the clinical data best. The first column
in Table III shows the estimated model parameters. During
model development we investigated the individual parameter
estimates grouped by the lenograstim administration.
The boxplots of the four parameters in Figure 4 highlight
that ktr and γ were significantly increased in the model without
consideration of an absoprtion model for patients who received
lenograstim administrations. After extending the model with
the s.c. absorption model and two transit compartments the
parameter values of γ were almost equal between the two
groups whereas the ktr values only approached to a small
degree. Values of slope were higher and the WBC steady
state values were slightly lower in the group of lenograstim
administrations. The visual predicitive check in Figure 3(b)
underlines the good match between model and clinical data.
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Fig. 3: (a) Cyclewise measured white blood cell (WBC) counts from two datasets with different colors for the datasets and
lenograstim administration (blue: with Leno (Ulm), green: no Leno (Ulm), black: no Leno (MD)). At time point 0 first Ara-C
infusion starts. Cycles in which lenograstim was administered show a rapid WBC increase during WBC recovery.
(b) Visual predictive check (VPC), derived by 1000 simulations with the final parameter estimates from the myelosuppression
model with two transit compartments (fourth column of Table II), for circulating WBCs (G/L) versus time (day). Black dots
are the measured WBC counts. Black and blue lines show the median and 2.5th and 97.5th percentiles of measurements and
model predictions, respectively. The shaded areas represent the 95% confidence intervals around the 2.5th, 50th and 97.5th
percentiles of the model predictions.
TABLE II: Medians of individual mean absolute errors (MAE)
and root mean squared errors (RMSE) with standard deviations
in paranthesis for different myelosuppression models with and
without consideration of lenograstim. The consideration of
lenograstim (Leno) described via a single pathway absorption
model iteratively increases the model fits by the inclusion of
additional transit compartments (Transit) until the best fit was
achieved with two transit compartments.
Model noLeno noTransit oneTransit twoTransit threeTransit
#Transit – 0 1 2 3
Leno no yes yes yes yes
MAE 0.842(3.22) 0.812(3.34) 0.802(3.31) 0.797(3.31) 0.806(3.30)
RMSE 0.918(0.84) 0.901(0.86) 0.896(0.86) 0.893(0.86) 0.898(0.86)
Also the rapid increase of WBC counts during WBC recovery
was captured with a slight overprediction of the 50% and
97.5% percentiles before reaching steady state.
B. Modeling leukemic blasts
The PK/PD model was fitted to the clinical data with
and without consideration of the leukemic cell lineage. The
estimated parameter values are presented in the second and
third column of Table III. The leukemic blast lineage only
had a minor effect on the estimated parameter values with
an increase of the slope parameter and the variance of the
exponential error model.
The model performance of describing the clinically ob-
served circulating WBC counts and relative blast counts in
the BM is shown as visual predictive checks (VPCs) in
Figure 5. The median of observed WBC counts coincided
with the median of calculated WBC counts and fell within
TABLE III: Results of parameter estimations for different
PK/PD models and datasets. Shown are residuals (objective
value), parameter estimates of fixed effects, interindividual
variability as a coefficient of variation (CV%) and exponential
(exp.) residual errors as variance with relative standard errors
(RSEs) in brackets for in-sample and out-of-sample (without
measurements of the last consolidation cycle).
in-sample out-of-sample
Dataset cyclewise patientwise patientwise patientwise
Blasts no no yes yes
# patients 67 44 44 24
Fixed Effects (RSE%)
B 4.67(6) 4.67(7) 4.85(8) 4.50(11)
ktr 0.196(10) 0.236(3) 0.218(6) 0.224(7)
slope 10.1(3) 7.94(11) 8.53(8) 8.95(7)
γ 0.701(4) 0.651(4) 0.680(6) 0.679(7)
ka 3.16(3) 3.15(26) 3.20(21) 2.828(31)
x0l1 – – 0.029(28) 0.0434(19)
Interindividual Variability CV% (RSE%)
B 39.6(8) 40.9(12) 49.3(14) 47.2(16)
ktr 19.3(10) 14.3(22) 25.2(21) 25.4(20)
slope 42.1(13) 55.8(17) 11.8(24) 17.9(21)
γ 19.8(10) 19.7(16) 21.2(15) 23.3(26)
ka 103.3(16) 95.1(28) 58.6(34) 119.6(22)
x0blasts – – 67.9(23) 24.0(101)
Residual Error (RSE%)
Exp. error 0.152(9) 0.284(8) 0.315(8) 0.250(10)
or close to its 95% prediction interval (blue area). The 2.5th
percentile of the model shows an underestimation in the first
CC and the 97.5th model percentile shows overestimations in
all CCs. Considering the VPC of the blasts, the 95% prediction
intervals of the 50th and 97.5th percentiles indicated that the
model assumed a faster increase of blasts during the three CCs
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Fig. 4: Boxplots of final parameter values of ktr, γ, slope and B grouped by lenograstim administrations for models noLeno
and twoTransit (see Table II).
compared to the almost constant (2.5th and 50th percentiles)
and decreasing (97.5th percentile) dynamics observed within
the patients.
Figure 6 shows the influence of G-CSF administrations
(yes or no) and of varied G-CSF steady states on the WBC
recovery. Ara-C without lenograstim administration resulted
in a longer recovery time and a slightly lower WBC count
before the start of the second and third CC. As a further
consequence, the number of leukemic blasts in the BM was
higher and increased more over time, than to the leukemic
blast count when the actual treatment schedule of lenograstim
was conducted. A different G-CSF steady state affected the
recovery time, where lower steady-state values provoke an
overproduction of WBC counts, leading to a higher value than
the WBC steady state.
We investigated the out-of-sample prediction performance
of the final model with its extension to lenograstim and
leukemic blasts and analyzed the potential of different treat-
ment schedules derived by mathematical optimization.
Parameter estimation results for the data subset (compared
to Figure 1) are shown in Table III. Compared to the in-
sample parameter estimates, the values of B, ktr, slope and γ
are almost equal to the values derived from the whole dataset
and the values of ka and x0l1 are slightly decreased, respec-
tively increased. The prediction performance is visualized as
a goodness-of-fit plot in Figure 7. Both in-sample and out-
of-sample, the values are centered around the line of identity.
No systematic error is apparent, only a slight overprediction
of small WBC counts.
C. Model predictions and optimal treatment schedules
Using the final model and the individual parameter esti-
mates for 14 patients from above, we calculated optimized
individual treatment schedules. Optimal refers to a numerical
local optimization of (5) in the last CC. From the solutions,
we extracted the WBC nadir values and final time relative
blast counts in the BM. A comparison to the observed values
in Figure 9 shows that the optimized treatment schedules of
Ara-C and lenograstim achieved an increase in nadir values
for each patient (in median 4.2-fold higher values), although
relative BM blast counts were comparable to the observed ones
and below the clinically important threshold of 5%. Not shown
is that the median Ara-C amount was lower by approximately
60%.
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Fig. 5: Visual predictive checks (VPCs), derived by 1000 simulations, for circulating WBCs [G/L] and relative (rel.) blast counts
in the bone marrow (BM) [%] versus time [day]. Black dots are the measured WBC counts, respectively rel. blast counts in
the BM. Black and blue lines show the median and 2.5th and 97.5th percentiles of measurements and model predictions,
respectively. The shaded areas represent the 95% confidence intervals around the 2.5th, 50th and 97.5th percentiles of the
model predictions.
Three exemplary optimization results with detailed trajecto-
ries are shown in Figure 8, and the results for all 14 patients
are shown in the Supplement Material. While optimal timing
and dosages of Ara-C and lenograstim were personalized and
hence different for each considered patient, two qualitative
patterns could be observed. In pattern A, an additional Ara-
C administration period (and hence an additional CC) was
introduced, and the administration order was Ara-C, leno, Ara-
C, leno. In pattern B, the nadir was increased compared to the
clinical treatment schedule with the administration order leno,
Ara-C, leno. The amount of Ara-C was usually considerably
reduced. Figure 8 shows examples for patterns A (middle,
right) and B (left). Over all of the considered case studies,
pattern A arose 9 times and pattern B 5 times.
IV. DISCUSSION
The development, fitting, validation, and analysis of the
PK/PD model was performed in an iterative way starting with
the modification of the myelosuppression model provided by
Quartino and colleagues [11] to Ara-C and to the s.c. adminis-
tration of lenograstim and completed with the incorporation of
the leukemic blast lineage. Several parameter estimations were
performed to fit and validate the models. An analysis of the
estimated model parameters in Table III showed that the fixed
effects and interindividual variabilities were in the same ranges
in all the numerical studies, indicating that the general model
behavior was maintained despite model extensions. The values
of B were within the normal human WBC range of 4−10 G/L
and coincided with the values estimated in [34] and with the
neutrophil base value from Quartino et al. [11], assuming that
the relative amount of neutrophils ranges between 60− 70%.
Compared to published WBC baseline values for the model
by Friberg et al. ranging between 7 and 7.8 G/L [46], our
values were 2 − 3 G/L lower. The mean maturation times
of 102-122 hours are reasonable and fit into the range of
previously published values [34]. The value of γ was larger
compared to the model of Quartino et al. [11], which might
be due to the dense treatment schedules. The residual error
doubled from the cyclewise to patientwise management of
the data, assuming that interoccasional variabilities, which
were not the focus of this work and as a consequence not
modeled, might be one of the reasons for an increased model-
reality mismatch. This mismatch was further increased with
the consideration of relative blast counts in the third column
of Table III introducing an additional source of error.
We visualized the parameter estimates separately for cycles
in which lenograstim was administered or not to analyze the
influence of lenograstim on the parameter estimates. Figure 4
shows that the steady state value of WBC is lower for
patients receiving lenograstim, indicating that the demand of
exogenous G-CSF might be related to the patients’ WBC
steady states. In comparison to the estimated values of γ which
were almost equal between the two groups after modeling
the lenograstim administation, the transport rate ktr was still
increased for the patients who received lenograstim although
exogenous G-CSF already influenced proliferation and mat-
uration via the feedback term (xg/Bg). We suspect that the
higher values agglomerate biological phenomena that are not
correctly described or fully covered by the current model.
Nevertheless, the model exhibited the same behavior as in
clinical trials with pegfilgrastim [4], i.e., a prolonged WBC
recovery time of several days without G-CSF, compared to
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Fig. 6: WBC dynamics (solid black line) of the final model fitted to observed WBC counts of the first two consolidation
cycles (blue dots), and the Ara-C and lenograstim treatment schedules of one exemplary patient are shown. The last cycle is
used for model prediction and out-of-sample comparison. Simulated WBC dynamics for no lenograstim (dotted black line)
and for different G-CSF steady state values (from 20% to 140% of used value) are shown (solid gray lines). No lenograstim
administration prolonged WBC recovery time and lower/higher G-CSF steady state values shortened/prolonged WBC recovery.
Moreover, no lenograstim administration resulted in a slightly larger leukemic blast count (the red area indicates the difference
when compared to the actual treatment schedule shown in the third row).
Figure 6.
The model has several constant parameters that were fixed to
published values. As only WBC and relative BM blast counts
were observed, this was necessary to avoid overfitting and
obtain a good predictive accuracy. However, the interpretation
of parameter values could now be misleading, as incorrect
constants and modeling are usually compensated by parameter
values. A better data situation with additional G-CSF and Ara-
C concentration measurements would allow to identify further
parameters. A structural sensitivity analysis ([52], [53]) would
help to systematically investigate identifiability of parameters
assuming additional biomarker measurements.
The VPC in Figure 5 revealed that the model of leukemic
blasts is able to describe trends resepctively overpredicts the
measurements with its exponential behavior, leading to a
purely leukemic steady state after 4.6 month being in the
reported interval for remission before relapses occured [40].
This conservative model behavior was chosen to study the
impact of different treatment schedules on the increase of
leukemic cells and might not exactly represent the patients
actual leukemic blast dynamics. Therefore, the presented treat-
ment optimization results have to be considered with care
and further investigations and efforts have to be undertaken
to develop more advanced and reliable models for bringing
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Fig. 7: Goodness-of-fit plot visualizing observed versus individually calculated white blood cell (WBC) counts for 24 patients.
Models were cross validated using out-of-sample (from the last CC) WBC measurements (blue circles). Red cubes show
in-sample WBC measurements from the remaining first CCs.
optimized treatment schedules to clinics. As the number of
leukemic blasts in our model will eventually converge to a
purely leukemic steady state, we can only compare short-
term impacts of treatment schedules on leukemic blasts and
hence relapse probabilities. In the future, additional modeling
assumptions could be considered, e.g., stable steady states of
coexistence between leukemic and healthy cells achieved via
the inclusion of the leukemic blasts’ steady state value in
the zero-order production term of endogenous G-CSF or a
threshold value of leukemic blasts below which the immune
system could avoid a relapse for good. Modeling minimial
residual disease (MRD), proposed by multiple recent studies
as a strong prognostic marker for relapse in AML [54], [55],
[56], [57] might also be a promising alternative to leukemic
blasts. In the current study, no MRD information was available
such that we concentrated on a model describing the relative
blast count measurements. In the current study we focused
on dynamic deterministic models but the low number of
BM measurements might force future model development to
stochastic or survival analysis approaches as it was previously
done by [58] in their proposed stochastic MRD model.
In our previous model [34], secondary PD effect of Ara-
C were analyzed and an empirical model extension through
a second PD effect on the feedback term γ was proposed.
During model development, we tested a parameterized PD
effect. However, the evaluation criteria (such as the root mean
squared error or a cross-validation in which the model was
fitted to standard schedules and validated on dense schedules)
showed only a minor benefit resulting from the consideration
of Ara-C’s possible secondary effects. For this reason and
without any concentration-time profiles of Ara-Cm we decided
to neglect a secondary PD effect of Ara-C. To obtain a
physiologically-based PK and PD model of Ara-C including
secondary effects, further studies have to be performed to
analyze the mechanisms and metabolism of high-dosage Ara-
C [59] and its impact on dense treatment schedules.
The optimized individual treatments derived by solving
problem (5) rely on the mathematical model (1). Application
of the results to the real world is thus always under the assump-
tion that the model and a personalized parameter estimation
capture reality sufficiently well. This model-reality mismatch
is amplified when optimized results are calculated. It is well
known that optimization tends to exploit modeling errors as
the ones discussed above. Thus, all interpretations should be
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Fig. 8: Detailed optimization results for Patients 1, 2, and 3, respectively (same order as in Figure 9). The treatment schedules
of Ara-C and lenograstim in the last CC were optimized (black) and compared with the clinically applied treatment schedules
(red). Shown are WBC counts and relative blast counts in the bone marrow (BM, dotted lines) resulting from individual models.
Personalization was performed using in-sample measurements (blue dots) and clinical treatment schedules (blue lines) from all
but the last CC. The optimized schedules and the affected dynamics of WBC (solid black lines) qualitatively differ for each
patient. In (a), one later low-dose treatment and in (b), two intermediate-dose Ara-C treatments result in higher nadir values
compared to the measured values (red dots). In (c), the daily lenograstim administrations before and after the postponed Ara-C
treatment did not prevent a fall of WBCs below 1 G/L. Discontinuities in the dynamics of the relative (rel.) blast counts in
the bone marrow (BM) occur due to possible cyclewise cellularity changes in the measurement function (3).
considered very carefully and should be mainly seen as an
incentive for clinical trials to validate the conjectures derived
from simulations.
On the positive side, we went to great lengths to develop a
mathematical model that is as robust as possible for a variety
of different treatment schedules. This could not only become
a basis for individual decision support, but allowed for the
first time to quantify the potential of optimized treatment
schedules in terms of nadir values, blast counts, and overall
chemotherapy usage. We see the value of a more than 4-
times increased nadir as a strong motivation to continue
research in model-based treatment planning, even if the current
personalized mathematical models might not yet be a perfect
match to the situation of the patient for whom the data were
observed.
Additionally, the approach allows to apply a variety of
methods from mathematical optimization to get closer to
clinical practice. Stochastic optimization techniques result in
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optimized schedules that are more robust against modeling
and parameter uncertainties. The consideration of combina-
torial constraints restricting the administration of Ara-C and
lenograstim to plausible schedules would increase the appli-
cability of the optimized schedules in clinical practice. Multi-
objective optimization can provide Pareto fronts with respect
to key performance indicators (high WBC, low blasts, low
costs, low treatment time, . . . ) as already indicated in this
study.
The optimized treatment schedules demonstrated that a
60% (median) reduction in the amount of Ara-C and daily
administrations of lenograstim could lead to higher nadir
values compared to the clinical schedules (see Figure 9a).
The efficacy of the optimized treatment schedules was eval-
uated by comparing the optimized and measured relative
blast counts in the BM at the end of the last CCs (c.f.
Figure 9b). The first clinical impact of the exploration of
the optimized treatment schedules was the proposed admin-
istration of lenograstim before the start of Ara-C treatments,
similar to the FLAG protocol [60], as a prevention to mitigate
myelosuppression and increase leukemic blast death. For all 14
patients, lenograstim accomplished an increase in WBC count
before Ara-C treatment, leading to moderate myelosuppression
compared to the conducted treatment schedules (see Figure 9).
In the clinical trial from which the dataset was provided
[5], lenograstim administration was started nine days after
Ara-C treatment, reducing the WBC recovery time but not
necessarily achieving nadir values above 1 G/L. As we
considered the amount of lenograstim within the objective
function, we assessed the times that had the smallest or largest
impact either on WBC recovery or leukemic blast apoptosis.
We also performed calculations with a modified objective
function without consideration of WBC count and lenograstim
costs (α2 = α4 = 0). The optimized treatment schedules still
resulted in the administration of lenograstim every day. This
indicates that exogenous G-CSF has a beneficial influence on
the eradication of leukemic blasts. In our model and setting,
lenograstim adimistation not only reduced WBC recovery
times but also the leukemic blast counts (c.f. Figure 6). This
coincides with clinical findings [61]. However, the contrary
assumption also exists: exogenous G-CSF may lead to an
increased leukemic blast count. Until now, no evidence was
given which claim holds, and in general, no clinical trial with
long-term follow-up has shown an increase in mortality or
relapse rate if G-CSF was administered [62], [63]. As the
optimized treatment schedules propose daily administration
of lenograstim, the change from s.c. injections to continuous
intravenous infusions might be worth considering. However, it
was shown that the s.c. administration of G-CSF (filgrastim)
results in lower peaks but more prolonged and stable levels of
G-CSF compared with intravenous administration [6].
Considering short-term effects under the assumption of
rapidly evolving leukemic blasts, our results indicate that
two CCs with reduced doses of Ara-C can achieve the same
outcome as that achieved by one CC, with the benefit of
increased WBC nadir values. This pattern emerged in 9 out of
12 cases and coincides with published results for docetaxel-
induced neutropenia [64]. This result gives a partial answer
to the question of Schlenk regarding whether four cycles
of consolidation therapy are the best treatment choice [65].
The developed mathematical model and optimization approach
might help in the future to determine an optimal treatment
schedule for the whole consolidation phase.
V. CONCLUSION
We developed a PK/PD model for the consolidation phase of
AML patients treated with Ara-C and lenograstim. The model
was able to predict the dynamics of WBCs in consecutive
cycles and helped to understand the interaction between WBCs
and leukemic blasts and how they respond to different treat-
ment schedules. The developed model and the results from
the computational approach to optimize the administration of
Ara-C and lenograstim with respect to clinically important
outcomes are further steps toward providing personalized
medicine and decision-support tools for physicians [66]. Al-
though the mathematical model might not capture all relevant
processes accurately and a direct transfer of individually opti-
mized schedules into clinical practice is not recommended at
this stage, out results give for the first time a quantification of
the potential of mathematically optimized AML consolidation
treatment. The more than 4-fold higher WBC counts at nadir
at comparable simulated relative bone marrow blast counts are
encouraging to pursue this line of research.
APPENDIX
Figures 10 to 16 show detailed optimization results for 14
patients from the data set (those with at least two consolida-
tion cycles and relative bone marrow blast count measure-
ments). The plots are identical to those in Figure 8 from
the manuscript, and the number of patients from 1 to 14 is
identical to that in Figure 9. Optimal solution refers to the
objective function, the model, and constraints as specified in
the manuscript.
The treatment schedules of Ara-C and lenograstim in the last
CC were optimized (black) and compared with the clinically
applied treatment schedules (red). WBC counts and relative
blast counts in the bone marrow (BM) resulting from indi-
vidual models (blue dotted lines) are shown. Personalization
was performed using in-sample measurements (blue dots) and
clinical treatment schedules (blue lines) from all but the last
CC.
While optimal timing and dosages of Ara-C and lenograstim
were personalized and hence different for each considered
patient, two qualitative patterns are observed.
In pattern A, an additional Ara-C administration period (and
hence an additional CC) is introduced; the administration order
is Ara-C, lenograstim, Ara-C and lenograstim.
In pattern B, the nadir is increased compared to the clinical
treatment schedule with the administration order lenograstim,
Ara-C, lenograstim. The amount of Ara-C is usually consid-
erably reduced.
The pattern types (9 times A, 5 times B) are indicated in
the captions for convenience.
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Fig. 9: Comparison between clinical (observed) and optimized treatments with respect to white blood cell (WBC) count nadirs
(left) and relative (rel.) blast counts in the bone marrow (BM, right) for 14 patients. The nadirs are significantly higher, often
even above the leukopenia threshold, while the corresponding relative BM blasts are maintained in the same range as the
observed values and below the clinically important threshold of 5%.
TABLE IV: Final values of the multiobjective optimization
problem weights.
Patient α1 α2 α3 α4
1 .9 3. 0.001 0.007
2 .8 1. 0.0001 0.007
3 1.8 .8 0.0001 0.007
4 1. 2. 0.001 0.007
5 .35 1. 0.0001 0.007
6 1. 1. 0.0001 0.007
7 1.4 1. 0.0001 0.007
8 1. 1. 0.0001 0.007
9 1. 10. 0.0001 0.007
10 1.25 1. 0.001 0.007
11 1. 1. 0.001 0.007
12 .6 1. 0.0001 0.007
13 1. 1. 0.0001 0.007
14 .9 1. 0.001 0.007
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Fig. 10: Optimization results for Patient 1 (top, B) and 2 (bottom, A).
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Fig. 11: Optimization results for Patient 3 (top, A) and 4 (bottom, A).
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Fig. 12: Optimization results for Patient 5 (top, A) and 6 (bottom, A).
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Fig. 13: Optimization results for Patient 7 (top, B) and 8 (bottom, B).
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Fig. 14: Optimization results for Patient 9 (top, A) and 10 (bottom, B).
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Fig. 15: Optimization results for Patient 11 (top, B) and 12 (bottom, A).
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Fig. 16: Optimization results for Patient 13 (top, A) and 14 (bottom, B).
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